R&D Views & Analysis | pharmaphorum

Views & Analysis

R&D

Psychedelic treatments on cusp of approval, but questions re...

There is a new wave of psychedelic treatment moving through clinical trials targeting mental health conditions, and they are showing strong efficacy.

R&D

Green shoots and cautious optimism: Insights from BIO-Europe...

With thousands of pharma and biotech dealmakers attending last months’ BIO-Europe Spring, appetite for partnering looked alive and well.

R&D

Commercialising IVDs – The complex path towards access to ea...

Early diagnosis through the use of in vitro diagnostics (IVDs) plays a critical role in patient outcomes and in supporting the healthcare system as a whole.

R&D

Lung-I Cheng interview with Jonah Comstock at Reuters

Reuters Pharma USA 2024 – Lung-I Cheng

Cell and gene therapies were a major topic of discussion this year at Reuters Pharma USA in Philadelphia.

R&D

Jeffrey Meckler having an interview with Jonah Comstock

Reuters Pharma USA 2024 – Jeffrey Meckler

Most of the exciting work being done right now in cancer immunotherapy is centred on highly targeted approaches that aim to activate only the most necessary immune responses to eliminate a

R&D

Harnessing the velocity of biopharmaceutical advances

Today’s pharmaphorum podcast addresses the subject of speed – the velocity at which biopharma is bringing new therapies and medicines to market faster.